the goal of this study is to compare the efficacy of ustekinumab with infliximab for the treatment of ulcerative colitis aim of the study :
1. Compare effectiveness of ustekinumab versus infliximab therapy in remission achievement in UC patients.
2. Compare safety of ustekinumab therapy versus infliximab therapy in UC
3. To asses quality of life of ustekinumab therapy versus infliximab therapy in UC patients.

Start Date15 May 2025

Sponsor / Collaborator

Helwan University

NCT05725876

/ RecruitingPhase 1

Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis: a Prospective Pilot Intervention Study

Crohn's Disease (CD) and psoriasis are chronic inflammatory diseases. Ustekinumab is a humanized monoclonal antibody. Ustekinumab is expensive and primary non-response is high in both CD and psoriasis. Currently, there are no predictors of response to ustekinumab and the actual mechanism of action has not yet been elucidated. To clarify the mechanism of action and gain a better understanding of the high primary non-response rates, the University Medical Center Groningen (UMCG) developed a tracer fluorescently labeling ustekinumab. This study aims to gain insight into ustekinumab distribution and concentrations in the gut. The current study aims to identify the ustekinumab target cells in the inflamed gut mucosa and skin using quantitative fluorescence molecular endoscopy (qFME). By gaining insight into local ustekinumab concentrations, drug distribution, and by discovering target cells, we expect to gain insight into the mechanism of action of ustekinumab.

Start Date06 Jan 2025

Sponsor / Collaborator

University Medical Center Groningen

ChiCTR2400089219

/ RecruitingNot ApplicableIIT

Efficacy of Ustekinumab Optimization by Dual Initial Intravenous Doses in Patients with Perianal Fistulizing Crohn's disease- A Multicentre Prospective Randomized Controlled Study

Start Date04 Sep 2024

Sponsor / Collaborator-

100 Clinical Results associated with Ustekinumab

100 Translational Medicine associated with Ustekinumab

100 Patents (Medical) associated with Ustekinumab

3,371

Literatures (Medical) associated with Ustekinumab

01 Dec 2025·IMMUNOLOGIC RESEARCH

A patient with CVID-enteropathy successfully treated with ustekinumab

Article

Author: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark

CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.

01 Feb 2025·EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Combination vedolizumab and ustekinumab for refractory Crohn’s disease after immune checkpoint inhibitors

Article

Author: Zarker, Andrew W. ; Wang, Yinghong

13 Jan 2025·Endocrine Metabolic & Immune Disorders-Drug Targets

Oral Microbiota Associated with Clinical Efficacy of Ustekinumab in Crohn’s Disease

Article

Author: Xie, Rui ; Wang, Honggang ; Yu, Huiming ; Zhu, Yifan ; Xu, Feiyang ; He, Le ; Yang, Xiaozhong

Background::

Crohn’s Disease (CD) is a chronic inflammatory gastrointestinal disease. Ustekinumab (UST) has been utilized as a therapeutic option for CD patients. However, approximately 40-60% of patients exhibit an inadequate response to UST. Accumulating evidence has confirmed the involvement of oral bacteria in the development of CD. Nevertheless, the relationship between oral microbiota and the efficacy of UST therapy in CD patients has remained unexplored.

Materials and Methods::

We recruited 28 healthy individuals and 53 CD patients, 47 of whom completed the entire UST therapy. Oral samples and clinical data were collected. The clinical response and clinical remission were defined based on the CDAI score. Oral samples were analyzed by 16S rRNA gene sequencing. The analysis of sequence data was performed by QIIME and R.

Results::

We revealed the oral microbial difference between the Healthy Control (HC) group and the CD group. The enrichment of Fusobacteria, Leptotrichia, Capnocytophaga, and Campylobacter, and the diminution of Haemophilus and Rothia were observed in the CD group. Differences in oral microbiota were also identified among patients with different efficacy of UST. Compared to the response and remission groups, both the non-response and non-remission groups showed significantly higher levels of Fusobacteria and Leptotrichia. Predictive models for clinical response and clinical remission in UST were developed based on oral microbiota, with the Area Under the Curve (AUC) value of 0.944 and 0.930, respectively.

Conclusion::

Oral microbiota was relevant to the UST efficacy in patients with CD based on the predictive model. These findings suggest that oral microbiota could serve as a non-invasive prognostic biomarker for UST treatment in CD patients.

362

News (Medical) associated with Ustekinumab

22 Jan 2025

·www.investor.jnj.com

Johnson & Johnson Reports Q4 and Full-Year 2024 Results

2024 Fourth-Quarter reported sales growth of 5.3% to $22.5 Billion with operational growth of 6.7%* and adjusted operational growth of 5.7%* 2024 Fourth-Quarter Earnings per share (EPS) of $1.41 and Adjusted EPS of $2.04, both include $(0.22) due to acquired IPR&D charges related to V-Wave acquisition 2024 Full-Year reported sales growth of 4.3% to $88.8 Billion with operational growth of 5.9%* and adjusted operational growth of 5.4%*. Operational growth excluding COVID-19 Vaccine of 7.0%* 2024 Full-Year Earnings per share (EPS) of $5.79 and Adjusted EPS of $9.98, both include $(0.67) due to acquired IPR&D charges on various transactions throughout the year Significant pipeline progress including RYBREVANT + LAZCLUZE overall survival data, initiation of TAR-200 submission, and approval of investigational device exemption for our general surgery robotic system, OTTAVA Company issues guidance for 2025 with operational sales5 growth of 2.5% - 3.5%* and adjusted operational EPS of $10.75 - $10.95, reflecting strong growth of 8.7%* at the mid-point NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure. With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson.” Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations of Johnson & Johnson. Overall financial results Q4 Full Year ($ in Millions, expect EPS) 2024 2023 % Change 2024 2023 % Change Reported Sales $22,520 $ 21,395 5.3% $88,821 $ 85,159 4.3% Net Earnings $3,431 $4,132 (17.0)% $14,066 $13,326 5.6% EPS (diluted) $1.41 $1.70 (17.1)% $5.79 $5.20 11.3% Q4 Full Year Non-GAAP* ($ in Millions, except EPS) 2024 2023 % Change 2024 2023 % Change Operational Sales1,2 6.7% 5.9% Adjusted Operational Sales1,3 5.7% 5.4% Adjusted Operational Sales1,3 ex. COVID-19 Vaccine 5.9% 6.5% Adjusted Net Earnings1,4 $4,946 $5,562 (11.1)% $ 24,242 $ 25,409 (4.6)% Adjusted EPS (diluted)1,4 $2.04 $2.29 (10.9)% $9.98 $9.92 0.6% Free Cash Flow6,7 ~$19,800 $18,248 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine 6 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 7 Full year 2024 is estimated as of January 22, 2025. Full year 2023 includes approximately 8 months contribution from the Consumer Health segment. Note: values may have been rounded Regional sales results Q4 % Change ($ in Millions) 2024 2023 Reported Operational1,2 Currency Adjusted Operational1,3 U.S. $13,204 $12,009 10.0% 10.0 - 8.6 International 9,316 9,386 (0.7) 2.5 (3.2) 2.0 Worldwide $22,520 $21,395 5.3% 6.7 (1.4) 5.7 Full Year % Change ($ in Millions) 2024 2023 Reported Operational1,2 Currency Adjusted Operational1,3 U.S. $50,302 $46,444 8.3% 8.3 - 7.6 International 38,519 38,715 (0.5) 2.9 (3.4) 2.7 Worldwide $88,821 $85,159 4.3% 5.9 (1.6) 5.4 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Segment sales results Q4 % Change ($ in Millions) 2024 2023 Reported Operational1,2 Currency Adjusted Operational1,3 Innovative Medicine $14,332 $13,722 4.4% 6.1 (1.7) 6.3 MedTech 8,188 7,673 6.7 7.6 (0.9) 4.6 Worldwide $22,520 $21,395 5.3% 6.7 (1.4) 5.7 Full Year % Change ($ in Millions) 2024 2023 Reported Operational1,2 Currency Adjusted Operational1,3 Innovative Medicine $56,964 $54,759 4.0% 5.7 (1.7) 5.8 MedTech 31,857 30,400 4.8 6.2 (1.4) 4.7 Worldwide $88,821 $85,159 4.3% 5.9 (1.6) 5.4 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Full year 2024 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 7.5%*. Growth was driven primarily by DARZALEX (daratumumab), ERLEADA (apalutamide), CARVYKTI (ciltacabtagene autoleucel), and Other Oncology in Oncology, TREMFYA (guselkumab) in Immunology, and SPRAVATO (esketamine) in Neuroscience. Growth was partially offset by STELARA (ustekinumab) in Immunology and Other Neuroscience in Neuroscience. Including the COVID-19 Vaccine, Innovative Medicine worldwide operational sales grew 5.7%*. MedTech MedTech worldwide operational sales grew 6.2%*, with net acquisitions and divestitures positively impacting growth by 1.5%. Growth was driven primarily by electrophysiology products and Abiomed in Cardiovascular, previously referred to as Interventional Solutions, and wound closure products in General Surgery. Full-year 2025 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) January 2025 Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point 2.0% – 3.0% / 2.5% Operational Sales2,5 / Mid-point Change vs. Prior Year / Mid-point $90.9B – $91.7B / $91.3B 2.5% – 3.5% / 3.0% Estimated Reported Sales3,5 / Mid-point Change vs. Prior Year / Mid-point $89.2B – $90.0B / $89.6B 0.5% – 1.5% / 1.0% Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point $10.75 – $10.95 / $10.85 7.7% – 9.7% / 8.7% Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: January 2025 = $1.04 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Other modeling considerations will be provided on the webcast. Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com. Regulatory SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression1 Press Release European Commission approves LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer1 Press Release New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer1 Press Release Johnson & Johnson MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH SF Catheter1 Press Release Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis1 Press Release Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease1 Press Release European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer Press Release Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant Press Release U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients Press Release Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA (guselkumab) Press Release Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor Press Release Johnson & Johnson MedTech Receives IDE Approval for OTTAVA Robotic Surgical System Press Release Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease Press Release Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO / DARZALEX as subcutaneous monotherapy for high-risk smoldering multiple myeloma Press Release DARZALEX (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible Press Release Data Releases RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib1 Press Release Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting Press Release Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results Press Release Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 Press Release Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024 Press Release TREMFYA (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease Press Release New SPECTREM study findings reveal TREMFYA (guselkumab) effectively clears overlooked and undertreated plaque psoriasis Press Release Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress Press Release Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study Press Release Product Launch MENTOR MemoryGel Enhance Breast Implant Receives FDA Approval for Largest Size Breast Implants for Reconstruction Press Release Johnson & Johnson MedTech Receives FDA Approval for the VARIPULSE Pulsed Field Ablation Platform for the Treatment of Atrial Fibrillation2 Press Release Other Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.1 Press Release 1 Subsequent to the quarter 2 On January 5, 2025, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE cases. More information can be found in the Statement on VARIPULSE. Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:00 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations. About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com. Non-GAAP financial measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results. Note to investors concerning forward-looking statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company’s ability to realize the anticipated benefits from the separation of Kenvue Inc. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. 2024 2023 Total Operations Currency 2024 2023 $ 8,977 8,079 11.1 % 11.1 - $ 33,970 31,169 9.0 % 9.0 - 5,355 5,643 (5.1 ) (1.0 ) (4.1 ) 22,994 23,590 (2.5 ) 1.3 (3.8 ) 14,332 13,722 4.4 6.1 (1.7 ) 56,964 54,759 4.0 5.7 (1.7 ) 8,977 8,079 11.1 11.1 - 33,970 31,169 9.0 9.0 - 5,355 5,599 (4.4 ) (0.3 ) (4.1 ) 22,796 22,473 1.4 5.5 (4.1 ) 14,332 13,678 4.8 6.5 (1.7 ) 56,766 53,642 5.8 7.5 (1.7 ) 4,227 3,930 7.6 7.6 - 16,332 15,275 6.9 6.9 - 3,961 3,743 5.8 7.6 (1.8 ) 15,525 15,125 2.6 5.4 (2.8 ) 8,188 7,673 6.7 7.6 (0.9 ) 31,857 30,400 4.8 6.2 (1.4 ) 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 - 9,316 9,386 (0.7 ) 2.5 (3.2 ) 38,519 38,715 (0.5 ) 2.9 (3.4 ) 22,520 21,395 5.3 6.7 (1.4 ) 88,821 85,159 4.3 5.9 (1.6 ) 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 - 9,316 9,342 (0.3 ) 2.9 (3.2 ) 38,321 37,598 1.9 5.5 (3.6 ) $ 22,520 21,351 5.5 % 6.9 (1.4 ) $ 88,623 84,042 5.5 % 7.0 (1.5 ) FOURTH QUARTER TWELVE MONTHS Percent Change Percent Change 2024 2023 Total Operations Currency 2024 2023 Total Operations Currency $ 13,204 12,009 10.0 % 10.0 - $ 50,302 46,444 8.3 % 8.3 - 4,921 4,962 (0.8 ) (0.2 ) (0.6 ) 20,212 20,410 (1.0 ) (0.6 ) (0.4 ) 1,135 1,166 (2.7 ) 17.6 (20.3 ) 4,714 4,549 3.6 20.4 (16.8 ) 3,260 3,258 0.1 0.9 (0.8 ) 13,593 13,756 (1.2 ) 2.3 (3.5 ) 9,316 9,386 (0.7 ) 2.5 (3.2 ) 38,519 38,715 (0.5 ) 2.9 (3.4 ) $ 22,520 21,395 5.3 % 6.7 (1.4 ) $ 88,821 85,159 4.3 % 5.9 (1.6 ) FOURTH QUARTER TWELVE MONTHS Percent Change Percent Change 2024 2023 Total Operations Currency 2024 2023 Total Operations Currency $ 13,204 12,009 10.0 % 10.0 - $ 50,302 46,444 8.3 % 8.3 - 4,921 4,918 0.1 0.7 (0.6 ) 20,014 19,293 3.7 4.1 (0.4 ) 1,135 1,166 (2.7 ) 17.6 (20.3 ) 4,714 4,549 3.6 20.4 (16.8 ) 3,260 3,258 0.1 0.9 (0.8 ) 13,593 13,756 (1.2 ) 2.3 (3.5 ) 9,316 9,342 (0.3 ) 2.9 (3.2 ) 38,321 37,598 1.9 5.5 (3.6 ) $ 22,520 21,351 5.5 % 6.9 (1.4 ) $ 88,623 84,042 5.5 % 7.0 (1.5 ) 2024 2023 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) $ 22,520 100.0 $ 21,395 100.0 5.3 7,128 31.6 6,798 31.8 4.9 15,392 68.4 14,597 68.2 5.4 6,453 28.6 5,810 27.1 11.1 5,298 23.5 4,480 20.9 18.3 17 0.1 58 0.3 (144 ) (0.6 ) (212 ) (1.0 ) (161 ) (0.7 ) (421 ) (2.0 ) 42 0.2 56 0.3 3,887 17.3 4,826 22.6 (19.5 ) 456 2.1 694 3.3 (34.3 ) $ 3,431 15.2 $ 4,132 19.3 (17.0 ) - (83 ) $ 3,431 $ 4,049 $ 1.41 $ 1.70 (17.1 ) $ - $ (0.03 ) 2,427.1 2,430.7 11.7 % 14.4 % $ 5,421 24.1 $ 6,237 29.2 (13.1 ) $ 4,946 22.0 $ 5,562 26.0 (11.1 ) $ 2.04 $ 2.29 (10.9 ) 8.8 % 10.8 % 2024 2023 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) $ 88,821 100.0 $ 85,159 100.0 4.3 27,471 30.9 26,553 31.2 3.5 61,350 69.1 58,606 68.8 4.7 22,869 25.7 21,512 25.2 6.3 17,232 19.4 15,085 17.7 14.2 211 0.2 313 0.4 (577 ) (0.6 ) (489 ) (0.6 ) 4,694 5.3 6,634 7.8 234 0.3 489 0.6 16,687 18.8 15,062 17.7 10.8 2,621 3.0 1,736 2.1 51.0 $ 14,066 15.8 $ 13,326 15.6 5.6 - 21,827 $ 14,066 $ 35,153 $ 5.79 $ 5.20 11.3 $ - $ 8.52 2,429.4 2,560.4 15.7 % 11.5 % $ 28,979 32.6 $ 29,811 35.0 (2.8 ) $ 24,242 27.3 $ 25,409 29.8 (4.6 ) $ 9.98 $ 9.92 0.6 16.3 % 14.8 % 2024 2023 2024 2023 $3,431 $4,132 $14,066 $13,326 (16) 166 5,450 7,152 1,171 1,148 4,526 4,532 23 10 100 663 62 139 269 798 47 88 204 311 298 237 1,226 339 (68) (435) 306 641 17 58 211 313 (80) 75 (2,135) (2,694) 61 (56) 19 28 $4,946 $5,562 $24,242 $25,409 2,427.1 2,430.7 2,429.4 2,560.4 $2.04 $2.29 $9.98 $9.92 $2.05 $9.99 1 2 3 4 4.4 % 6.7 % 5.3 % 11.1 % 7.6 % 10.0 % (5.1 )% 5.8 % (0.7 )% (1.7 ) (0.9 ) (1.4 ) - - - (4.1 ) (1.8 ) (3.2 ) 6.1 % 7.6 % 6.7 % 11.1 % 7.6 % 10.0 % (1.0 )% 7.6 % 2.5 % (3.4 ) (1.2 ) (5.1 ) (1.7 ) (1.5 ) (0.6 ) 0.2 0.4 0.2 0.1 0.8 0.3 0.3 0.0 0.1 6.3 % 4.6 % 5.7 % 11.2 % 3.3 % 8.6 % (0.7 )% 6.1 % 2.0 % 0.4 0.2 0.0 0.0 0.7 0.4 6.7 % 4.6 % 5.9 % 11.2 % 3.3 % 8.6 % 0.0 % 6.1 % 2.4 % 4.0 % 4.8 % 4.3 % 9.0 % 6.9 % 8.3 % (2.5 )% 2.6 % (0.5 )% (1.7 ) (1.4 ) (1.6 ) - - - (3.8 ) (2.8 ) (3.4 ) 5.7 % 6.2 % 5.9 % 9.0 % 6.9 % 8.3 % 1.3 % 5.4 % 2.9 % (1.9 ) (0.7 ) (2.9 ) (1.0 ) (0.8 ) (0.3 ) 0.1 0.4 0.2 0.1 0.8 0.3 0.2 0.1 0.1 5.8 % 4.7 % 5.4 % 9.1 % 4.8 % 7.6 % 1.5 % 4.7 % 2.7 % 1.8 1.1 0.0 0.0 4.2 2.6 7.6 % 4.7 % 6.5 % 9.1 % 4.8 % 7.6 % 5.7 % 4.7 % 5.3 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS % Change % Change 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency $ 2,856 3,033 -5.9 % -5.9 % - $ 11,355 11,539 -1.6 % -1.6 % - 1,383 1,562 -11.5 % -6.5 % -5.0 % 6,473 6,513 -0.6 % 4.0 % -4.6 % 4,238 4,595 -7.8 % -6.1 % -1.7 % 17,828 18,052 -1.2 % 0.4 % -1.6 % 231 294 -21.4 % -21.4 % - 1,009 1,143 -11.7 % -11.7 % - 9 35 -73.3 % -73.3 % - 98 147 -33.0 % -33.0 % - 117 100 16.5 % 22.9 % -6.4 % 497 549 -9.5 % -5.0 % -4.5 % 359 429 -16.5 % -15.0 % -1.5 % 1,605 1,839 -12.8 % -11.4 % -1.4 % 262 258 1.3 % 1.3 % - 1,082 1,124 -3.8 % -3.8 % - 321 244 32.1 % 44.2 % -12.1 % 1,108 1,073 3.3 % 13.2 % -9.9 % 583 502 16.2 % 22.1 % -5.9 % 2,190 2,197 -0.3 % 4.5 % -4.8 % 1,699 1,786 -4.9 % -4.9 % - 6,720 6,966 -3.5 % -3.5 % - 650 967 -32.7 % -29.6 % -3.1 % 3,641 3,892 -6.4 % -3.3 % -3.1 % 2,349 2,753 -14.7 % -13.6 % -1.1 % 10,361 10,858 -4.6 % -3.4 % -1.2 % 654 657 -0.6 % -0.6 % - 2,443 2,147 13.7 % 13.7 % - 295 252 16.9 % 21.7 % -4.8 % 1,227 999 22.8 % 27.6 % -4.8 % 949 910 4.2 % 5.6 % -1.4 % 3,670 3,147 16.6 % 18.1 % -1.5 % 0 2 - 3 11 -74.1 % -74.1 % - 0 0 - - - 0 0 - - - 0 2 3 11 -74.1 % -74.1 % - 331 353 -6.4 % -6.4 % - 1,354 1,500 -9.8 % -9.8 % - 443 498 -11.2 % -9.8 % -1.4 % 2,042 2,918 -30.0 % -29.3 % -0.7 % 774 852 -9.2 % -8.4 % -0.8 % 3,396 4,418 -23.1 % -22.7 % -0.4 % 0 0 - - - 0 0 - - - 0 44 198 1,117 -82.4 % -82.4 % 0.0 % 0 44 198 1,117 -82.4 % -82.4 % 0.0 % 7 9 -10.1 % -10.1 % - 31 35 -10.0 % -10.0 % - 315 299 5.0 % 5.6 % -0.6 % 1,241 1,115 11.2 % 11.2 % 0.0 % 322 307 4.6 % 5.1 % -0.5 % 1,272 1,150 10.6 % 10.6 % 0.0 % 321 341 -5.8 % -5.8 % - 1,311 1,446 -9.4 % -9.4 % - 86 98 -12.9 % -8.9 % -4.0 % 401 408 -1.7 % 1.1 % -2.8 % 407 439 -7.4 % -6.5 % -0.9 % 1,712 1,854 -7.7 % -7.1 % -0.6 % 1 4 -53.1 % -53.1 % - 11 19 -41.0 % -41.0 % - 43 58 -24.2 % -22.4 % -1.8 % 203 278 -26.7 % -23.9 % -2.8 % 45 62 -26.1 % -24.4 % -1.7 % 214 297 -27.6 % -25.0 % -2.6 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS % Change % Change 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency 1,148 1,022 12.3 % 12.3 % - 4,398 4,065 8.2 % 8.2 % - 628 780 -19.6 % -16.8 % -2.8 % 2,718 3,076 -11.6 % -7.8 % -3.8 % 1,775 1,801 -1.5 % -0.3 % -1.2 % 7,115 7,140 -0.4 % 1.3 % -1.7 % 33 39 -12.8 % -12.8 % - 134 230 -41.7 % -41.7 % - 125 142 -11.5 % -7.7 % -3.8 % 507 554 -8.4 % -4.1 % -4.3 % 159 180 -11.7 % -8.8 % -2.9 % 641 783 -18.1 % -15.1 % -3.0 % 796 733 8.6 % 8.6 % - 3,125 2,897 7.9 % 7.9 % - 267 278 -4.0 % -1.8 % -2.2 % 1,097 1,218 -9.9 % -7.1 % -2.8 % 1,063 1,011 5.1 % 5.7 % -0.6 % 4,222 4,115 2.6 % 3.4 % -0.8 % 269 180 50.1 % 50.1 % - 929 589 57.8 % 57.8 % - 28 26 7.1 % 12.5 % -5.4 % 148 100 48.2 % 51.2 % -3.0 % 297 206 44.6 % 45.3 % -0.7 % 1,077 689 56.4 % 56.8 % -0.4 % 49 71 -31.0 % -31.0 % - 210 349 -39.8 % -39.8 % - 206 334 -38.1 % -35.4 % -2.7 % 965 1,204 -19.8 % -15.1 % -4.7 % 255 404 -36.9 % -34.6 % -2.3 % 1,175 1,553 -24.3 % -20.7 % -3.6 % 3,019 2,285 32.2 % 32.2 % - 10,854 8,462 28.3 % 28.3 % - 2,476 2,334 6.1 % 10.6 % -4.5 % 9,926 9,199 7.9 % 12.1 % -4.2 % 5,497 4,618 19.0 % 21.3 % -2.3 % 20,781 17,661 17.7 % 19.8 % -2.1 % 304 145 - 869 469 85.2 % 85.2 % - 31 13 94 30 334 159 963 500 92.7 % 92.7 % 0.0 % 1,799 1,395 28.9 % 28.9 % - 6,588 5,277 24.8 % 24.8 % - 1,285 1,155 11.3 % 17.0 % -5.7 % 5,082 4,467 13.8 % 19.1 % -5.3 % 3,084 2,550 20.9 % 23.5 % -2.6 % 11,670 9,744 19.8 % 22.2 % -2.4 % 342 287 19.0 % 19.0 % - 1,282 1,065 20.3 % 20.3 % - 442 361 22.4 % 25.7 % -3.3 % 1,717 1,322 29.8 % 32.9 % -3.1 % 784 647 20.9 % 22.7 % -1.8 % 2,999 2,387 25.6 % 27.3 % -1.7 % 250 255 -2.0 % -2.0 % - 1,020 1,051 -3.0 % -3.0 % - 481 533 -9.6 % -6.8 % -2.8 % 2,018 2,214 -8.8 % -6.3 % -2.5 % 731 788 -7.2 % -5.2 % -2.0 % 3,038 3,264 -6.9 % -5.2 % -1.7 % 108 102 5.6 % 5.6 % - 418 334 25.3 % 25.3 % - 38 24 59.9 % 71.6 % -11.7 % 131 61 146 126 15.8 % 18.0 % -2.2 % 549 395 38.8 % 39.8 % -1.0 % 9 9 -7.3 % -7.3 % - 34 50 -32.2 % -32.2 % - 127 191 -33.6 % -30.7 % -2.9 % 597 837 -28.6 % -24.6 % -4.0 % 135 201 -32.4 % -29.6 % -2.8 % 631 887 -28.8 % -25.0 % -3.8 % 208 90 - 643 215 - 74 58 25.5 % 30.6 % -5.1 % 288 269 7.1 % 10.4 % -3.3 % 282 148 90.4 % 92.4 % -2.0 % 931 484 92.5 % 94.3 % -1.8 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS % Change % Change 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency 819 733 11.6 % 11.6 % - 3,143 2,697 16.5 % 16.5 % - 274 282 -3.2 % 1.2 % -4.4 % 1,140 1,117 2.0 % 8.2 % -6.2 % 1,092 1,017 7.4 % 8.7 % -1.3 % 4,282 3,815 12.3 % 14.1 % -1.8 % 385 368 4.8 % 4.8 % - 1,520 1,292 17.7 % 17.7 % - 160 169 -5.2 % -2.5 % -2.7 % 664 681 -2.4 % 1.1 % -3.5 % 545 536 1.7 % 2.5 % -0.8 % 2,184 1,973 10.7 % 11.9 % -1.2 % 391 348 12.3 % 12.3 % - 1,511 1,326 13.9 % 13.9 % - 75 70 5.7 % 11.2 % -5.5 % 307 255 20.1 % 27.3 % -7.2 % 465 419 11.2 % 12.1 % -0.9 % 1,817 1,582 14.9 % 16.1 % -1.2 % 42 18 - 112 79 41.8 % 41.8 % - 40 45 -10.0 % -0.4 % -9.6 % 169 182 -6.9 % 8.2 % -15.1 % 82 61 32.3 % 39.3 % -7.0 % 281 260 7.9 % 18.3 % -10.4 % 805 652 23.3 % 23.3 % - 2,866 2,906 -1.4 % -1.4 % - 153 185 -17.6 % -15.1 % -2.5 % 696 765 -9.1 % -7.1 % -2.0 % 957 837 14.3 % 14.8 % -0.5 % 3,562 3,671 -3.0 % -2.6 % -0.4 % 676 525 28.5 % 28.5 % - 2,373 2,365 0.3 % 0.3 % - - - - - - - - - - - 676 525 28.5 % 28.5 % - 2,373 2,365 0.3 % 0.3 % - 130 127 1.5 % 1.5 % - 494 541 -8.8 % -8.8 % - 153 185 -17.6 % -15.1 % -2.5 % 696 765 -9.1 % -7.1 % -2.0 % 281 312 -9.8 % -8.3 % -1.5 % 1,189 1,306 -8.9 % -7.8 % -1.1 % 8,977 8,079 11.1 % 11.1 % - 33,970 31,169 9.0 % 9.0 % - 5,355 5,643 -5.1 % -1.0 % -4.1 % 22,994 23,590 -2.5 % 1.3 % -3.8 % $ 14,332 $ 13,722 4.4 % 6.1 % -1.7 % $ 56,964 54,759 4.0 % 5.7 % -1.7 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS % Change % Change 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency $ 1,221 971 25.8 % 25.8 % - $ 4,513 3,633 24.2 % 24.2 % - 841 698 20.6 % 22.0 % -1.4 % 3,194 2,717 17.6 % 20.9 % -3.3 % 2,062 1,669 23.6 % 24.2 % -0.6 % 7,707 6,350 21.4 % 22.8 % -1.4 % 681 667 2.1 % 2.1 % - 2,738 2,458 11.4 % 11.4 % - 640 572 11.7 % 13.3 % -1.6 % 2,529 2,230 13.4 % 17.0 % -3.6 % 1,321 1,239 6.6 % 7.3 % -0.7 % 5,267 4,688 12.3 % 14.0 % -1.7 % 308 276 11.3 % 11.3 % - 1,213 1,066 13.7 % 13.7 % - 77 64 19.8 % 21.1 % -1.3 % 284 240 18.2 % 20.3 % -2.1 % 384 340 12.9 % 13.2 % -0.3 % 1,496 1,306 14.5 % 14.9 % -0.4 % 202 - - 442 - - 56 - - 122 - - 258 - - 564 - - 31 28 11.1 % 11.1 % - 120 109 10.7 % 10.7 % - 68 61 12.1 % 12.3 % -0.2 % 260 247 5.3 % 7.3 % -2.0 % 99 89 11.8 % 12.0 % -0.2 % 380 356 6.9 % 8.4 % -1.5 % 1,460 1,425 2.4 % 2.4 % - 5,689 5,525 3.0 % 3.0 % - 856 843 1.6 % 2.5 % -0.9 % 3,470 3,417 1.5 % 3.0 % -1.5 % 2,315 2,268 2.1 % 2.5 % -0.4 % 9,158 8,942 2.4 % 3.0 % -0.6 % 272 266 2.5 % 2.5 % - 1,057 996 6.2 % 6.2 % - 146 132 10.6 % 11.7 % -1.1 % 581 564 3.0 % 4.6 % -1.6 % 418 398 5.2 % 5.6 % -0.4 % 1,638 1,560 5.0 % 5.6 % -0.6 % 238 242 -1.5 % -1.5 % - 922 896 2.9 % 2.9 % - 160 144 10.7 % 11.3 % -0.6 % 623 559 11.3 % 12.4 % -1.1 % 398 387 3.1 % 3.3 % -0.2 % 1,545 1,456 6.1 % 6.5 % -0.4 % 514 487 5.5 % 5.5 % - 2,013 1,949 3.3 % 3.3 % - 250 255 -1.9 % -0.5 % -1.4 % 1,036 1,030 0.6 % 2.1 % -1.5 % 764 741 3.0 % 3.5 % -0.5 % 3,049 2,979 2.3 % 2.9 % -0.6 % 434 430 1.1 % 1.1 % - 1,696 1,684 0.7 % 0.7 % - 300 311 -3.6 % -2.9 % -0.7 % 1,230 1,263 -2.6 % -1.2 % -1.4 % 735 742 -0.9 % -0.6 % -0.3 % 2,926 2,947 -0.7 % -0.1 % -0.6 % REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS % Change % Change 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency 1,038 1,047 -0.9 % -0.9 % - 4,003 4,031 -0.7 % -0.7 % - 1,469 1,484 -1.0 % 1.4 % -2.4 % 5,842 6,006 -2.7 % 0.6 % -3.3 % 2,507 2,530 -0.9 % 0.4 % -1.3 % 9,845 10,037 -1.9 % 0.1 % -2.0 % 478 468 2.0 % 2.0 % - 1,838 1,833 0.2 % 0.2 % - 673 698 -3.6 % -1.6 % -2.0 % 2,650 2,837 -6.6 % -3.5 % -3.1 % 1,151 1,167 -1.4 % -0.1 % -1.3 % 4,488 4,671 -3.9 % -2.0 % -1.9 % 560 579 -3.1 % -3.1 % - 2,165 2,198 -1.5 % -1.5 % - 795 785 1.4 % 4.0 % -2.6 % 3,192 3,168 0.8 % 4.3 % -3.5 % 1,357 1,364 -0.5 % 1.0 % -1.5 % 5,358 5,366 -0.2 % 2.0 % -2.2 % 509 487 4.5 % 4.5 % - 2,128 2,086 2.0 % 2.0 % - 794 721 10.2 % 12.2 % -2.0 % 3,018 2,986 1.1 % 3.7 % -2.6 % 1,303 1,208 7.9 % 9.1 % -1.2 % 5,146 5,072 1.5 % 3.0 % -1.5 % 396 374 6.0 % 6.0 % - 1,684 1,626 3.6 % 3.6 % - 541 508 6.4 % 8.5 % -2.1 % 2,049 2,076 -1.3 % 1.8 % -3.1 % 937 882 6.3 % 7.4 % -1.1 % 3,733 3,702 0.8 % 2.6 % -1.8 % 113 114 -0.4 % -0.4 % - 444 460 -3.4 % -3.4 % - 252 212 19.3 % 21.1 % -1.8 % 969 910 6.5 % 8.2 % -1.7 % 365 326 12.4 % 13.6 % -1.2 % 1,413 1,370 3.2 % 4.3 % -1.1 % 4,227 3,930 7.6 % 7.6 % - 16,332 15,275 6.9 % 6.9 % - 3,961 3,743 5.8 % 7.6 % -1.8 % 15,525 15,125 2.6 % 5.4 % -2.8 % $ 8,188 $ 7,673 6.7 % 7.6 % -0.9 % $ 31,857 30,400 4.8 % 6.2 % -1.4 % FOURTH QUARTER TWELVE MONTHS Percent Change Percent Change 2024 2023 Total Operations Currency 2024 2023 Total Operations Currency $ 8,977 8,079 11.1 11.1 - $ 33,970 31,169 9.0 9.0 - 5,355 5,643 (5.1 ) (1.0 ) (4.1 ) 22,994 23,590 (2.5 ) 1.3 (3.8 ) 14,332 13,722 4.4 6.1 (1.7 ) 56,964 54,759 4.0 5.7 (1.7 ) - - - - - - - - - - - 44 198 1,117 (82.4 ) (82.4 ) 0.0 - 44 198 1,117 (82.4 ) (82.4 ) 0.0 8,977 8,079 11.1 11.1 - 33,970 31,169 9.0 9.0 - 5,355 5,599 (4.4 ) (0.3 ) (4.1 ) 22,796 22,473 1.4 5.5 (4.1 ) 14,332 13,678 4.8 6.5 (1.7 ) 56,766 53,642 5.8 7.5 (1.7 ) 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 - 9,316 9,386 (0.7 ) 2.5 (3.2 ) 38,519 38,715 (0.5 ) 2.9 (3.4 ) 22,520 21,395 5.3 6.7 (1.4 ) 88,821 85,159 4.3 5.9 (1.6 ) - - - - - - - - - - - 44 * * * 198 1,117 (82.4 ) (82.4 ) 0.0 - 44 * * * 198 1,117 (82.4 ) (82.4 ) 0.0 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 - 9,316 9,342 (0.3 ) 2.9 (3.2 ) 38,321 37,598 1.9 5.5 (3.6 ) $ 22,520 21,351 5.5 6.9 (1.4 ) $ 88,623 84,042 5.5 7.0 (1.5 ) $ 4,921 4,962 (0.8 ) (0.2 ) (0.6 ) $ 20,212 20,410 (1.0 ) (0.6 ) (0.4 ) - 44 * * * 198 1,117 (82.4 ) (82.4 ) 0.0 $ 4,921 4,918 0.1 0.7 (0.6 ) $ 20,014 19,293 3.7 4.1 (0.4 ) Innovative Medicine MedTech Unallocated Worldwide Total 2024 2023 2024 2023 2024 2023 2024 2023 4,009 4,238 72 404 (194 ) 184 3,887 4,826 28.0 % 30.9 % 0.9 % 5.3 % -0.9 % 0.9 % 17.3 % 22.6 % 685 747 486 401 - - 1,171 1,148 17 - - 58 - - 17 58 (41 ) 17 (29 ) 149 54 - (16 ) 166 (50 ) (112 ) (18 ) (59 ) - (264 ) (68 ) (435 ) 2 55 60 84 - - 62 139 12 175 268 62 18 - 298 237 - - 47 88 - - 47 88 23 10 - - - - 23 10 4,657 5,130 886 1,187 (122 ) (80 ) 5,421 6,237 32.5 % 37.4 % 10.8 % 15.5 % -0.5 % -0.4 % 24.1 % 29.2 % 3,698 3,357 1,600 1,123 5,298 4,480 25.8 % 24.5 % 19.5 % 14.6 % 23.5 % 20.9 % 390 390 540 540 540 390 540 390 Innovative Medicine MedTech Unallocated Worldwide Total 2024 2023 2024 2023 2024 2023 2024 2023 18,919 18,246 3,740 4,669 (5,972 ) (7,853 ) 16,687 15,062 33.2 % 33.3 % 11.7 % 15.4 % -6.7 % -9.2 % 18.8 % 17.7 % 2,772 2,983 1,754 1,549 - - 4,526 4,532 211 206 - 107 - - 211 313 358 (108 ) (14 ) 190 5,106 7,070 5,450 7,152 (76 ) 362 30 (102 ) 352 381 306 641 102 479 167 319 - - 269 798 66 175 1,015 164 145 - 1,226 339 - - 204 311 - - 204 311 100 663 - - - - 100 663 22,452 23,006 6,896 7,207 (369 ) (402 ) 28,979 29,811 39.4 % 42.0 % 21.6 % 23.7 % -0.4 % -0.5 % 32.6 % 35.0 % 13,529 11,963 3,703 3,122 17,232 15,085 23.8 % 21.8 % 11.6 % 10.3 % 19.4 % 17.7 % 390 390 1,250 1,250 540 540 1,250 540 390 1,790 390 $ 7,128 (1,162 ) (20 ) (153 ) (18 ) - - 5,775 6,453 (4 ) 6,449 5,298 - (25 ) (6 ) 5,267 (161 ) (9 ) 16 - (145 ) 68 (17 ) (248 ) 17 (17 ) - - 42 (42 ) - 456 171 (158 ) 4 3 80 (34 ) 9 5 (61 ) 475 3,431 1,000 142 13 59 218 (34 ) 38 18 61 4,946 $ 6,798 (1,131 ) (83 ) (42 ) (12 ) - 5,530 5,810 (8 ) 5,802 4,480 (16 ) (38 ) (1 ) 4,425 (421 ) (17 ) (166 ) - (221 ) 435 3 (387 ) 58 (58 ) - 56 (56 ) - 694 175 (134 ) 13 16 30 (191 ) 16 - 56 675 4,132 973 300 45 123 207 (244 ) 72 10 (56 ) 5,562 $ 27,471 (4,517 ) (35 ) (359 ) (84 ) (8 ) 22,468 22,869 (16 ) - 22,853 17,232 (69 ) (104 ) (25 ) 17,034 4,694 (9 ) (5,450 ) - (798 ) (306 ) (67 ) (1,936 ) 211 (211 ) - - - - - 234 (234 ) - 2,621 644 1,066 47 45 302 (29 ) 38 22 (19 ) 4,737 14,066 3,882 4,384 164 224 924 335 166 78 19 24,242 $ 26,553 (4,511 ) (309 ) (133 ) (189 ) 21,411 21,512 (29 ) 21,483 15,085 (32 ) (149 ) (99 ) 14,805 6,634 (21 ) (7,152 ) - (307 ) (641 ) (375 ) (1,862 ) 313 (313 ) - - 489 (489 ) - 1,736 707 1,505 70 157 52 (9 ) 57 155 (28 ) 4,402 13,326 3,825 5,647 243 641 287 650 254 508 28 25,409 Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com

Drug ApprovalClinical ResultVaccineImmunotherapyFinancial Statement

16 Jan 2025

·www.prnewswire.com

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

BIMZELX® (bimekizumab-bkzx) is now commercially available by prescription in the United States in a 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX The single-injection device offers convenience for patients requiring a 320 mg dose of BIMZELX with single-injection administration ATLANTA, Jan. 16, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These are in addition to the currently available 1 mL device administration options, each containing 160 mg of BIMZELX. With the new presentations, patients requiring a 320 mg dose of BIMZELX will have options for single-injection administration.1 "With five new FDA-approved indications for BIMZELX in just over a year, we've had the opportunity to reach a wider range of people living with chronic inflammatory conditions who have long been in need of new treatment options," said Camille Lee, Head of U.S. Immunology, UCB. "With the addition of a single-injection administration regimen, we are further expanding options and enhancing the treatment experience for individuals with moderate-to-severe plaque psoriasis, active psoriatic arthritis with coexistent moderate-to-severe plaque psoriasis, and moderate-to-severe hidradenitis suppurativa who receive a 320 mg dose of BIMZELX." The approval of the 320 mg single-injection administration option in October 2024 was supported by data from studies evaluating the bioequivalence of BIMZELX 320 mg given as one 2 mL subcutaneous injection, and BIMZELX 320 mg given as two 1 mL subcutaneous injections, in healthy study participants.1 In the U.S., the indications for BIMZELX where a 320 mg dose is recommended are adults with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis (PsA) with coexistent moderate-to-severe plaque psoriasis, and adults with moderate-to-severe hidradenitis suppurativa.1* In all other indications, adults with active PsA, adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS), a 160 mg dose is recommended.1 Through BIMZELX Navigate®, UCB offers tailored patient support to patients who have been prescribed BIMZELX. Upon enrollment, patients will be offered support from a dedicated Nurse Navigator. This licensed, registered nurse will be available to discuss treatment goals, provide training assistance to patients on how to administer BIMZELX, connect eligible patients to copay support, and keep patients up-to-date about their BIMZELX shipment and insurance coverage status. Patients who have been prescribed BIMZELX may enroll in BIMZELX Navigate at . UCB is actively engaging in access conversations with payers, with a focus on our patient value strategy and keeping the patient at the center of these discussions. Based on these conversations, we are progressing well toward our goal to enable access to our medicines for people who need them, in a way that is sustainable for patients, society, and UCB. Full affordability information can be found at ucb-usa.com/Sustainability/Affordability/Bimzelx-Pricing-Info and . For additional medical information, patient assistance or any other information, please call UCBCares® at 1-844-599-CARE (2273) or visit askucbcares.com. Notes to Editors: About BIMZELX® (bimekizumab-bkzx) BIMZELX is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.1 IL-17A and IL-17F are key contributors of chronic inflammation and damage across multiple tissues, with IL-17F increasing over time.1, 2-4 IL-17F is over-expressed in skin and highly elevated in the serum of patients with PSO, PsA, nr-axSpA, AS, and HS.1, 2-5 The approved indications for BIMZELX in the U.S. are:1 Plaque psoriasis: BIMZELX is approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Psoriatic arthritis: BIMZELX is indicated for the treatment of adult patients with active psoriatic arthritis Non-radiographic axial spondyloarthritis: BIMZELX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation Ankylosing spondylitis: BIMZELX is indicated for the treatment of adult patients with active ankylosing spondylitis Hidradenitis suppurativa: BIMZELX is indicated for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa *The recommended dosage of BIMZELX in patients is as follows: Plaque Psoriasis: Administer 320 mg by subcutaneous injection at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing 120 kg or more, consider a dose of 320 mg every 4 weeks after Week 16. Psoriatic Arthritis: Administer 160 mg by subcutaneous injection every 4 weeks. For patients with coexisting moderate-to-severe plaque psoriasis, use the dosage and administration for plaque psoriasis. Non-Radiographic Axial Spondyloarthritis: Administer 160 mg by subcutaneous injection every 4 weeks. Ankylosing Spondylitis: Administer 160 mg by subcutaneous injection every 4 weeks. Hidradenitis Suppurativa: Administer 320 mg by subcutaneous injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14 and 16, then every 4 weeks thereafter. See full prescribing information for recommendations regarding missed doses, preparation and administration instructions. Please see Important Safety Information below and full U.S. Prescribing Information at . BIMZELX U.S. IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION Suicidal Ideation and Behavior BIMZELX (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been definitively established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, instruct to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment. Infections BIMZELX may increase the risk of infections, including serious infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves. Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment. Liver Biochemical Abnormalities Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis. Inflammatory Bowel Disease Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs. Immunizations Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX. Most Common Adverse Reactions Most common (≥ 1%) adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, other candida infections, and fatigue. Most common (≥ 2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. Most common (≥ 2%) adverse reactions in non-radiographic axial spondyloarthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections. Most common (≥ 2%) adverse reactions in ankylosing spondylitis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, injection site pain, rash, and vulvovaginal mycotic infection. For further information, contact UCB: Investor Relations Antje Witte T +32.2.559.94.14 email [email protected] Brand Communications Nicole Herga T +1.773.960.5349 email [email protected] About UCB UCB, Brussels, Belgium () is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCBUSA. Forward looking statements This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future. UCB is providing this information, including forward-looking statements, only as of the date of this press release. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. References BIMZELX® (bimekizumab-bkzx) U.S. Prescribing Information. . Accessed January 2025. Glatt S, Baeten D, Baker T et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–32. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475-486. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate-to-severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487-498. Rumberger BE, Boarder EL, Owens SL, et al. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. Inflamm Res. 2020;69(10):967-973. US-BK-2401977 Date of preparation: January 2025 BIMZELX®, UCBCares®, and BIMZELX Navigate® are registered trademarks of the UCB Group of Companies. ©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved. SOURCE UCB WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalClinical Result

15 Jan 2025

·endpts.com

Drugmakers tout limits of IRA impact ahead of next negotiation round

Johnson & Johnson, AstraZeneca and Pfizer leaders reiterated during the JP Morgan Healthcare Conference that the federal government’s price negotiations still won’t have a material effect on their bottom lines. As early as this week, CMS may release the names of the next 15 drugs subject to Medicare drug price negotiations for 2027. The Trump administration is taking over on Monday. J&J CEO Joaquin Duato said Monday during a fireside chat that the company’s revenue estimate for 2025 includes the IRA’s impact. J&J’s Xarelto, Stelara, and Imbruvica were among the drugs selected in the first round of negotiations for 2026, and Duato says those products “are not core to our growth.” “So we feel confident about being able to deliver in our estimates,” he said, according to an AlphaSense transcript. The IRA-negotiated prices for a 30-day supply of J&J’s drugs for 2026 are: $197 for Xarelto, $4,695 for Stelara and $9,319 for Imbruvica. Those prices are 62%, 66% and 38% lower than the drugs’ list prices, respectively. AstraZeneca’s chief financial officer and executive director Aradhana Sarin noted in a presentation on Tuesday that the company faces “headwinds,” including “pricing pressures” and the IRA. But she said she still expects “the base business to have strong momentum in terms of revenue going into 2025,” according to an AlphaSense transcript. Sarin said the company expects total revenue to rise by a “high teens percentage,” and that it will report its full-year results on Feb. 6. AstraZeneca’s blockbuster drug Farxiga was included in the first round of negotiations and has a negotiated price of $178, or 68% lower than the list price. Meanwhile, Pfizer CEO Albert Bourla said during a fireside chat that he expects a “$1 billion negative impact because of the IRA,” according to an AlphaSense transcript. He still says he expects “strong performance” from the company’s newer acquisition products, including Biohaven Pharmaceuticals’ migraine drug Nurtec. “The IRA clearly affects us, but there are also many bigger things that are affected by [the] IRA, which is the tech and all the renewables and a lot of the stuff. For a complete rebuild … I don’t know if they would go for anything like that now, but improvements on the IRA we will certainly advocate for,” Bourla said during a lunch with reporters. Pfizer’s Eliquis was included in the first round of IRA drug price negotiations and has a negotiated price of $231, which is 56% lower than the list price. The IRA’s other drug pricing provisions include a $2,000 annual out-of-pocket cap and new manufacturer discounts, among other provisions. Pfizer said in a December press release that it expects an unfavorable impact from a new manufacturer discount program , which requires companies to provide certain discounts on applicable drugs to Medicare beneficiaries. The first round of negotiations, which ended in August, is expected to save Medicare $6 billion in 2026. Negotiated prices for the second round of drugs are slated to take effect on Jan. 1, 2027, according to CMS guidance. Manufacturers of the second round’s selected drugs have until Feb. 28 to agree to participate in the negotiations. — Jaimy Lee contributed reporting.

100 Deals associated with Ustekinumab

External Link

KEGG	Wiki	ATC	Drug Bank
D09214	Ustekinumab	L04AC05	DB05679

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Colitis, Ulcerative	AU	Janssen-Cilag Pty Ltd.	28 Jul 2009
Crohn Disease	AU	Janssen-Cilag Pty Ltd.	28 Jul 2009
Arthritis, Psoriatic	EU	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	IS	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	LI	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	NO	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	EU	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	IS	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	LI	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	NO	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	EU	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	IS	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	LI	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	NO	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	EU	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	IS	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	LI	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	NO	Janssen-Cilag International NV	15 Jan 2009
Ulcerative colitis, active moderate	EU	Janssen-Cilag International NV	15 Jan 2009
Ulcerative colitis, active moderate	IS	Janssen-Cilag International NV	15 Jan 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Juvenile Idiopathic Arthritis	Phase 3	US	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	AR	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	DK	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	FR	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	DE	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	IT	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	PL	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	ES	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	TR	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	GB	Janssen Research & Development LLC	30 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04882072 (CTgov)	Phase 3	Takayasu Arteritis	14	placebo+ustekinumab (Double-blind: Placebo)	cfcojgtfxs(dphfbspmju) = tnfhjzlcwp nnjaabujum (enzreidyqu, ptkiovigij - rlwmjxttcy) View more	-	02 Dec 2024
				Ustekinumab (Double-blind: Ustekinumab)	cfcojgtfxs(dphfbspmju) = ygrsgizhtt nnjaabujum (enzreidyqu, alblbzjbge - xurobujbdr) View more
NCT04629196 (CTgov)	Phase 4	Crohn Disease	12	Ustekinumab (IV Weight-Based Induction Dose)	vcjmtzeikr(wpsobkwuzp) = szztsszlkb zqormzinis (kxnwnonrqr, sguoikrqcr - jpozublfqj) View more	-	05 Nov 2024
				Ustekinumab (Standard Subcutaenous Dose)	vcjmtzeikr(wpsobkwuzp) = pyvaxiewtx zqormzinis (kxnwnonrqr, szyhjnerkw - dnqpnusekp) View more
UEGW2024	Not Applicable	Crohn Disease	-	Ustekinumab as 1st line biologic treatment	iusrujhrui(unncmopblk) = 63.9% (108/169) of patients experienced adverse events vplrcsproa (qoehlmkskb ) View more	-	13 Oct 2024
				Ustekinumab as 2nd line biologic treatment
NCT03942120 (K-STAR, Pubmed \| Inflamm Bowel Dis) Manual	Not Applicable	Crohn Disease Maintenance \| Induction	464	Ustekinumab	aehutwghtv(tznumnqgzr) = tmanbzaytr ctvbjveacc (vwwkfnweeb ) View more	Positive	03 Aug 2024
				Ustekinumab (At week 52 to 66)	aehutwghtv(tznumnqgzr) = wbekayiale ctvbjveacc (vwwkfnweeb ) View more
NCT04093531 (CTgov)	Phase 1	Primary Sjögren's syndrome	12	ustekinumab	iqqnncplqz(uuvprovxab) = dyysmltfls boqglhjkoi (emxjxwqfoi, qrcyrdlsku - hugpguztew) View more	-	25 Jun 2024
DDW2024	Not Applicable	Colitis, Ulcerative	-	Ustekinumab	rhxzyilyfb(kkjltypjhl) = ledsyptycn ocirkkmrbc (ujckoxysdj ) View more	-	21 May 2024
				Vedolizumab	rhxzyilyfb(kkjltypjhl) = qenoeslipt ocirkkmrbc (ujckoxysdj ) View more
DDW2024	Not Applicable	Crohn Disease	-	Ustekinumab	pvliqzsivr(mnfytypalc) = spcgnshuvf zhnbtqligv (dkxecrrriz ) View more	-	20 May 2024
NCT04089345 (Pubmed \| Clin Gastroenterol Hepatol) Manual	Phase 3	Pouchitis	22	ustekinumab intravenously at baseline (∼6mg/kg)	dlokmbwzhg(kwhxinpdsp) = bqlfqawiom gzbtefbunk (wcfrkdvmkt ) View more	Positive	14 May 2024
NCT03981744 (CTgov)	Phase 3	Dermatomyositis	51	placebo+ustekinumab (Placebo)	rtwcngkhxu(fnjgmqllrp) = gaaadjwcyo gnyqgjnhbn (ixgatacfvz, pyyevpchjr - qvjnvbhthr) View more	-	13 May 2024
				Ustekinumab (Ustekinumab)	rtwcngkhxu(fnjgmqllrp) = vovcrlrmoe gnyqgjnhbn (ixgatacfvz, bdmrrbnrkx - dwlplsmuva) View more
ACR2023	Not Applicable	Arthritis, Psoriatic First line	186	UST+MTX	pfefgdwxxl(jphahwhonl) = gwrxbsfqed hxoxwumznv (dulsrohnlo ) View more	Positive	13 Nov 2023
				UST+PBO	pfefgdwxxl(jphahwhonl) = nomvtfncvx hxoxwumznv (dulsrohnlo ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ustekinumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation